Lithium and the Thyroid: Hypothyroidism, Goiter, and Rare Hyperthyroidism

Lithium causes hypothyroidism in 10-30% of long-term users, especially women with TPO antibodies. Goiter is common and overt hyperthyroidism is rare. Routine TSH monitoring is essential, and most cases respond to added levothyroxine without stopping lithium.

Why lithium affects the thyroid

Lithium concentrates inside the thyroid gland at three to four times the plasma level and interferes with several steps of thyroid hormone production and release [C2][C3]. The dominant mechanism is inhibition of T4 and T3 release from thyroglobulin stored in the follicle — lithium blocks the colloid-to-blood step, so even when the gland synthesizes hormone, less of it reaches the circulation [C2][C4]. Secondary effects include reduced iodine uptake, impaired iodotyrosine coupling, and altered thyroglobulin structure [C2][C3].

The pituitary responds to lower circulating T4 by raising TSH, which drives the gland harder. Over time the result is a clinical picture that overlaps with primary hypothyroidism — elevated TSH, low or low-normal free T4, and often a diffuse, soft goiter from chronic TSH stimulation [C3][C4]. In patients with pre-existing thyroid autoimmunity, lithium also appears to accelerate lymphocytic infiltration of the gland, which is why positive TPO antibodies at baseline are the single strongest predictor of who will become hypothyroid on lithium [C3][C4][C7].

Clinical pattern and timeline

The thyroid effects of lithium are not uniform — they show up at different points and in different forms [C3][C4]:

• First weeks: a transient TSH rise is common and may resolve on its own as the gland adapts. This usually doesn't require treatment [C3].
• Months 6–24: subclinical hypothyroidism (TSH elevated, free T4 normal) appears in roughly 20-40% of patients depending on the cohort. Risk is concentrated in women, in patients over 50, and in those with positive TPO antibodies at baseline [C3][C4].
• Long-term (years): overt hypothyroidism develops in 10-30% of long-term users. Goiter — usually diffuse, soft, and non-tender — is found in 30-50% of long-term users and reflects the chronic TSH drive on the gland [C2][C4].
• Rare: hyperthyroidism, including silent thyroiditis and Graves'-like presentations, occurs in fewer than 1-2% of patients. The mechanism is thought to be release of stored hormone during a destructive thyroiditis triggered by lithium-induced glandular injury [C4].

Women are affected three to five times more often than men, and the combination of female sex, age over 50, and TPO positivity carries the highest cumulative risk [C3][C4].

What recovers on adequate levothyroxine

For most patients who develop hypothyroidism on lithium, the management is simple: add levothyroxine and continue lithium [C1][C3]. Mood stability on lithium is hard-won, and switching mood stabilizers carries a real relapse risk — so endocrinology and psychiatry generally treat the thyroid problem rather than the medication [C3][C4]. With adequate replacement:

• TSH returns to the normal range over 6-8 weeks, with dose titration as needed [C1].
• Energy, cognitive symptoms, and cold intolerance typically improve within weeks to a few months [C1][C8].
• Goiter often shrinks once TSH is well controlled, though long-standing nodular goiters may persist [C4].
• Mood does not destabilize from levothyroxine itself when dosed to a normal TSH; over-replacement (suppressed TSH) can trigger anxiety or mania and should be avoided [C1][C3].

If lithium is later stopped for an unrelated reason, the thyroid often recovers — but not always. Patients who were TPO-positive before lithium frequently remain hypothyroid and need to stay on levothyroxine [C4][C7].

When the picture doesn't fit — differential

A few scenarios need a different workup rather than just adding levothyroxine [C3][C4]:

1. Suppressed TSH on lithium: think lithium-induced thyrotoxicosis — either silent thyroiditis (release of stored hormone) or, much less commonly, true Graves'. A radioiodine uptake scan (or anti-TSH-receptor antibodies) sorts these out, and management depends on which one it is [C4][C6].
2. Painful, tender goiter: not typical of lithium effect and warrants imaging to rule out subacute thyroiditis or a nodular process [C4].
3. Rapidly growing nodule: nodules in the lithium-treated thyroid follow the same workup as nodules in anyone else — ultrasound, and biopsy if features warrant it [C4].
4. Persistent hypothyroid symptoms with a normal TSH: check ferritin, vitamin D, and B12, and reconfirm TSH stability; lithium itself does not cause symptoms when thyroid hormone is in range [C1][C8].

What does NOT help

Several approaches are commonly tried but lack evidence for managing lithium's thyroid effects [C1][C3][C4]:

• High-dose iodine or kelp supplements to "support" the thyroid. Excess iodine in a TPO-positive, lithium-treated patient can worsen hypothyroidism and trigger Hashimoto flares [C7].
• Switching levothyroxine to "natural desiccated thyroid" without a specific indication. The American Thyroid Association recommends levothyroxine as first-line for hypothyroidism of any cause, including lithium-induced [C1].
• Selenium for lithium-related TPO antibody rise. Selenium has modest evidence in non-lithium Hashimoto's but no trial evidence specifically for lithium-induced thyroid disease [C7].
• Stopping lithium "to protect the thyroid." Unless an alternative mood stabilizer is clinically indicated, the standard practice is to treat the thyroid and keep the lithium working [C3][C4].

Practical guidelines

1. Get a baseline before starting lithium — TSH, free T4, TPO antibodies, and a thyroid exam. TPO positivity at baseline is the strongest individual risk factor for later hypothyroidism [C3][C4][C5].
2. Repeat TSH 6 months after starting, then every 6-12 months long-term. Real-world data show that even this minimum schedule is often missed; ask your endocrinologist or prescriber to confirm it's on your calendar [C5].
3. If TSH rises above the lab's upper limit, your endocrinologist will usually add levothyroxine rather than stop lithium. Mood-stabilizer continuity matters [C3][C4].
4. Expect a soft, diffuse goiter to be common and benign — it reflects TSH drive and often shrinks once thyroid hormone is replaced [C4].
5. Watch for hyperthyroid symptoms (palpitations, tremor, weight loss, heat intolerance). Rare on lithium, but they warrant urgent TSH and free T4 testing [C4].
6. Tell every clinician you're on lithium — including new endocrinologists, surgeons, and ER physicians. The thyroid picture on lithium is its own entity [C3].

Frequently asked questions

Should I stop lithium if my TSH rises? Usually no. Lithium-induced hypothyroidism is managed by adding levothyroxine while continuing lithium. Stopping a stabilizing mood medication is rarely the right answer — your endocrinologist and psychiatrist will coordinate dosing [C3][C4].

Will lithium cure or fix my Hashimoto's? No. If anything, lithium tends to worsen the natural course of Hashimoto's by accelerating gland infiltration. Patients with positive TPO antibodies are at the highest risk of developing hypothyroidism on lithium and usually need lifelong levothyroxine afterward [C3][C4][C7].

How often should I get TSH tested on lithium? Baseline before starting, then around 6 months in, then every 6-12 months thereafter. Real-world audits show a meaningful fraction of patients go a year or more without testing — confirm the schedule is on the calendar [C3][C5].

Can lithium cause hyperthyroidism? Yes, but rarely — under 2% of long-term users. It's typically a destructive thyroiditis (transient release of stored hormone) rather than true Graves'. New palpitations, tremor, or unexplained weight loss should trigger TSH and free T4 testing [C4].

Will my goiter go away? Often, yes. A soft, diffuse goiter from chronic TSH drive typically shrinks once levothyroxine brings TSH back into range. Long-standing nodular goiters may persist and need ultrasound follow-up [C4].

Bottom line

Lithium concentrates in the thyroid and blocks hormone release, producing hypothyroidism in 10-30% of long-term users, goiter in 30-50%, and rare cases of thyroiditis or hyperthyroidism [C2][C3][C4]. Women, patients over 50, and people with positive TPO antibodies are at the highest risk [C3][C4][C7]. The standard management is adding levothyroxine while continuing lithium — switching mood stabilizers is rarely the right trade-off [C1][C3]. Baseline thyroid labs before starting and every 6-12 months while on therapy catch nearly all cases early enough to treat without disrupting psychiatric stability [C5].